Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program

Lignende værker

• First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
  af: Schuler, Martin, et al.
  Udgivet: (2019)
• Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
  af: Wang, Shouzheng, et al.
  Udgivet: (2019)
• Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?
  af: Mitsudomi, Tetsuya, et al.
  Udgivet: (2016)
• Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial
  af: Wu, Yi-Long, et al.
  Udgivet: (2018)
• Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
  af: Passaro, Antonio, et al.
  Udgivet: (2013)